Hepatology International

Article	Citations
The safety profile of endoscopic variceal ligation in patients with esophageal varices	101
Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression	84
HBV in pregnancy: time to consider tenofovir alafenamide (TAF)	83
Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial	73
Metabolically healthy obese and MAFLD: does weight status alone matter?	66
Platelets in acute liver failure: an innocent bystander or instigator?	65
Diagnosis of significant liver fibrosis in patients with chronic hepatitis B using a deep learning-based data integration network	58
‘First week’ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure	56
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD	56
Antibiotic prophylaxis in upper gastrointestinal bleeding with Child-Pugh A cirrhosis: need for objective infection markers and broader studies	53
Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis	51
Development of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection	50
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease	48
Effect of microbiota metabolites on the progression of chronic hepatitis B virus infection	48
Good outcomes of living donor liver transplant in primary sclerosing cholangitis: an experience from North India	44
Predictive value of soluble PD-1 for HBsAg loss in HbeAg-negative patients with chronic hepatitis B: results from a prospective study	42
Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma	41
Biomarkers of endothelial dysfunction in alcoholic hepatitis	41
Pure laparoscopic versus open left lateral hepatectomy in pediatric living donor liver transplantation: a review and meta-analysis	38
Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria	38
Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis	37
Response to: “Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues”	36
Antioxidant, selenium and risk of nonalcoholic fatty liver disease, more than causality	34
Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies	34
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy	33

Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy	33
Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study	33
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets	33
Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis	31
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis	31
The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes	30
Prospects for treatment of esophageal varices considering the safety of endoscopic band ligation	30
Identifying the early predictors of non-response to steroids in patients with flare of autoimmune hepatitis causing acute-on-chronic liver failure	29
A novel radiomics–platelet nomogram for the prediction of gastroesophageal varices needing treatment in cirrhotic patients	28
Image-matching digital macro-slide—a novel pathological examination method for microvascular invasion detection in hepatocellular carcinoma	27
Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis	27
Metabolic dysfunction associated fatty liver disease in healthy weight individuals	27
Liver-derived extracellular vesicles from patients with hepatitis B virus-related acute-on-chronic liver failure impair hepatic regeneration by inhibiting on FGFR2 signaling via miR-218-5p	27
Reply to: “developing real‑world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond”	27
Drug–drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study	26
Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis	26
The overview of the deep learning integrated into the medical imaging of liver: a review	26
Targeting immuno-metabolism and anti-viral immune responses in chronic hepatitis B	25
Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures	25
Letter to the editor: Treating portal vein thrombosis in cirrhosis: is anticoagulation therapy overestimated?	25
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan	25
The relationship between CXCR6+CD8+T cells and clinicopathological parameters in patients with primary biliary cholangitis	24
Correction to: Targeting ferroptosis in hepatocellular carcinoma	24
Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain	24
Connection between HPS and ACLF: a solution of chaos?	24
Role of splenic hepatic elastography ratio in differentiating non-cirrhotic portal fibrosis and chronic liver disease in children and adolescents	23
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients	23
The dynamic patterns of metabolic-associated fatty liver disease and its severity and risk of cardiovascular disease	23
Gut microbes associated with functional cure of chronic hepatitis B	23
Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study	22
Combined computed tomography and magnetic resonance imaging improves diagnosis of hepatocellular carcinoma ≤ 3.0 cm	22
Fecal microbiota transplantation in alcoholic hepatitis: new treatment paradigm or a shot in the dark?	22
Volumetric assessment and clinical predictors of cirrhosis in patients undergoing hepatectomy for hepatocellular carcinoma with presumed normal liver function	22
Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis	22
MAFLD, patient-centred care, and APASL	22
Downregulated VISTA enhances Th17 differentiation and aggravates inflammation in patients with acute-on-chronic liver failure	22
The impact of artificial liver support system on intestinal microbiota and serum bile acid profiles in patients with acute-on-chronic liver failure: a prospective cohort study	21
Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1–AXL signal relay in liver cancer cells	21
Correction to: Exosomal miR-200b-3p induce macrophage polarization by regulating transcriptional repressor ZEB1 in hepatocellular carcinoma	21
Dynamic assessments of hepatic encephalopathy and ammonia levels predict mortality in acute-on-chronic liver failure	21
Benefit of adjuvant radiotherapy for gallbladder cancer: a comparability-based meta-analysis	21
The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma	21
Maternal and perinatal outcome in pregnancies complicated with portal hypertension: a systematic review and meta-analysis	21
Diabetes is associated with poor short-term prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure	21
ChIP-seq analysis found IL21R, a target gene of GTF2I–the susceptibility gene for primary biliary cholangitis in Chinese Han	21
AARC score and urine NGAL predict terlipressin non-response and mortality in patients with acute-on-chronic liver failure	20
Distinct course of portal hypertension in patients with cirrhosis with gastric variceal bleeding as their first decompensation: a propensity score-matched study	20
The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study	20
Increased risk of cancer in patients with primary sclerosing cholangitis	20
A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis	20

Liver decompensation: the yard stick that measures indications and adverse effects of human albumin infusion	20
Comment on: Low-risk individuals with primary biliary cholangitis and significant liver stiffness: prognosis and treatment	20
Diagnostic yield and novel candidate genes by next generation sequencing in 166 children with intrahepatic cholestasis	20
Sleep patterns, genetic susceptibility, and risk of cirrhosis among individuals with nonalcoholic fatty liver disease	20
The association between visceral adipocyte hypertrophy and NAFLD in subjects with different degrees of adiposity	19
Distinctly altered lipid components in hepatocellular carcinoma relate to impaired T cell-dependent antitumor immunity	19
Tadalafil improves erectile dysfunction and quality of life in men with cirrhosis: a randomized double blind placebo controlled trial	19
Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis	19
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD	19
Skeletal muscle alterations indicate poor prognosis in cirrhotic patients: a multicenter cohort study in China	19
Gender differences in non-alcoholic fatty liver disease in obese children and adolescents: a large cross-sectional study	19
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients	19
Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals	19
Liver fat and a perturbed metabolic milieu: a consilience of factors driving liver cancer development	18
Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study	18
A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma	18
Low skeletal muscle mass is associated with more severe histological features of non-alcoholic fatty liver disease in male	18
Drug-induced liver injury from herbal and dietary supplements: a problem in the East and West alike	17
Reduction of natural killer cells is associated with poor outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure	17
Diet-derived antioxidants and nonalcoholic fatty liver disease: a Mendelian randomization study	17
Interferon therapy improves survival in patients with hepatitis B virus-related hepatocellular carcinoma after curative surgery: a meta-analysis	17
Genetic predisposition of metabolic dysfunction-associated steatotic liver disease: a population-based genome-wide association study	17
Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease	17
The effectiveness of combination therapy with interferon and nucleoside analogs in pediatric patients with chronic hepatitis B: a systematic review and meta-analysis	17
Explainable attention-enhanced heuristic paradigm for multi-view prognostic risk score development in hepatocellular carcinoma	17
Modified and alternative Baveno VI criteria based on age for ruling out high-risk varices in patients with compensated cirrhosis	17
Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study	16
Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycle	16
Integrated genomic analyses of hepatocellular carcinoma	16
CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway	16
PIVKA-II combined with alpha-fetoprotein for the diagnostic value of hepatic tumors in children: a multicenter, prospective observational study	15
Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality:A nationwide study	15
Oxidative stress triggers hyperdynamic circulation via central neural activation in portal hypertensive rats	15
Diagnosis and management of pediatric acute liver failure: consensus recommendations of the Indian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ISPGHAN)	15
Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma	15
Consensus on the secondary prevention of primary liver cancer	15
Correction to: Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells	15
The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion	14
Longitudinal progression of clinical variables associated with graded liver injury in COVID-19 patients	14
Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective	14
Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma	14
PIRO-CIC model can predict mortality and futility of care in critically ill cirrhosis patients in the intensive care unit	14
Reconsiderations for the liver donation from a living donor: addressing hepatic steatosis with weight loss preconditioning	14
New progress towards elimination of mother-to-child transmission of hepatitis B virus in China	13
Hepatitis B virus-related intrahepatic cholangiocarcinoma originates from hepatocytes	13
Predictive power of portal pressure gradient remeasured shortly after transjugular intrahepatic portosystemic shunt	13
Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis	13
Global burden of cirrhosis and liver cancer due to alcohol: the past, present, and the future	13
Low platelets: a new and simple prognostic marker for patients with hepatitis E virus-related acute liver failure	12
Editorial: The safety profile of endoscopic variceal ligation in patients with esophageal varices. Authors’ reply	12
Gut-microbiome composition and function in progression of alcohol-associated liver disease: going beyond western experiences	12
Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019	12
miR-98-5p as a novel biomarker suppress liver fibrosis by targeting TGFβ receptor 1	12
Nomograms should be noted	12
Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease	12
APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients	12
Clinical practice guidelines on hemochromatosis: Asian Pacific Association for the Study of the Liver	12
Influence of shunt occlusion on liver volume and functions in hyperammonemic cirrhosis patients having large porto-systemic shunts: a randomized control trial	12
Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure: a propensity score matched study from the APASL ACLF Research Consortium (AARC)	12
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort	12
Correction to: Infuence of shunt occlusion on liver volume and functions in hyperammonemic cirrhosis patients having large porto-systemic shunts: a randomized control trial	11
Development of an intervention system for linkage-to-care and follow-up for hepatitis B and C virus carriers	11
Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease	11
Carbohydrate-deficient transferrin is a sensitive marker of alcohol consumption in fatty liver disease	11
Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period	11
Liver fibrosis is associated with impaired bone mineralization and microstructure in obese individuals with non-alcoholic fatty liver disease	11
Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection	11
Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study	11
Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma	11
Comments on: Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis	11
How non-alcoholic fatty liver disease and cirrhosis affect the heart	11
Reply to: The best predictive model for post-SVR HCC: can it be universal?	11
Expanding treatment indications in chronic hepatitis B: Should we treat all patients?	11
Exosomal miR-200b-3p induce macrophage polarization by regulating transcriptional repressor ZEB1 in hepatocellular carcinoma	11
Presence of sarcopenia identifies a special group of lean NAFLD in middle-aged and older people	11
Developing real-world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond	11
Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA	11
Autophagy and extracellular vesicles in the liver endothelium: friends or foes?	11
Non-alcoholic fatty liver disease frequency and associated factors at admission of acute stroke	11
Correction to: Complementary role of peripheral and central autonomic nervous system on insulin-like growth factor-1 activation to prevent fatty liver disease	11

Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment	11
Comparison of the prognostic models for mortality in idiosyncratic drug-induced liver injury	11
The upregulation of Annexin A2 by TLR4 pathway facilitates lipid accumulation and liver injury via blocking AMPK/mTOR-mediated autophagy flux during the development of non-alcoholic fatty liver diseas	11
Determination of Turkish norms of psychometric tests for diagnosing minimal hepatic encephalopathy and proposal of a high sensitive screening test battery	11
Synthetic miR-26a mimics delivered by tumor exosomes repress hepatocellular carcinoma through downregulating lymphoid enhancer factor 1	11
Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes	11
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma	10
Functional cure is associated with younger age in children undergoing antiviral treatment for active chronic hepatitis B	10
Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma	10
The causes of death in patients with nonalcoholic steatohepatitis following liver transplantation stratified using pre-liver transplant BMI	10
Safety of right liver donation after improving steatosis through weight loss in living donors: a retrospective study	10
Efficacy and safety of precision-guided transjugular extrahepatic portosystemic shunt (TEPS) in the management of cavernous transformation of the portal vein with portal hypertension: a case series	10
Impact of plasma exchange on bilirubin reduction and neurological impairment in infantile acute liver failure	10
Identification of PANoptosis-relevant subgroups and predicting signature to evaluate the prognosis and immune landscape of patients with biliary tract cancer	10
Letter: Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial	10
Risk stratification for patients with primary biliary cholangitis: early versus advanced-stage or non-cirrhosis versus cirrhosis?	10
Hepatopulmonary syndrome is related to the development of acute-on-chronic liver failure and poor prognosis in cirrhotic patients	10
Management of spontaneous portosystemic shunts at the time of liver transplantation: treatment or observation? Results of a systematic review	10
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024	10
Acute kidney injury stage 1a increases mortality of patients with cirrhosis: a prospective multicenter cohort study	10
Key considerations in portal vein thrombosis management	10
Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome	10
Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure	10
Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC	10
Complications of congenital portosystemic shunts: liver tumors are affected by shunt severity, but pulmonary and neurocognitive associations are not	10
Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis	10
GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial	10
Regarding the role of post-transplant inflammatory cytokine signature on predicting tumor recurrence after liver transplantation for hepatocellular carcinoma	10
Survival analysis between laparoscopic and open hepatectomy for hepatocellular carcinoma: a meta-analysis based on reconstructed time-to-event data	10
Adipokine/hepatokines profiling of fatty liver in adolescents and young adults: cross-sectional and prospective analyses of the BCAMS study	10
Albumin, filamin-A and cytokeratin 19 help distinguish intrahepatic cholangiocarcinoma from extrahepatic adenocarcinoma	9
Complementary role of peripheral and central autonomic nervous system on insulin-like growth factor-1 activation to prevent fatty liver disease	9
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients	9
Consensus on the tertiary prevention of primary liver cancer	9
Functional B cell deficiency promotes intrahepatic HBV replication and impairs the development of anti-HBV T cell responses	9
Effect of diabetes on mortality and liver transplantation in alcoholic liver cirrhotic patients with acute decompensation	9
Establishment and validation of a prognostic model for hepatitis B virus‑related acute-on-chronic liver failure patients with bacterial infection	9
Enhancing the evaluation and management of MAFLD: a call for comprehensive assessments and social work integration	9
Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy	9
Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues	9
HBV, antivirals, and immunoglobulins after liver transplantation: all that glitters is not gold	9
Metabolic interventions improve HBV envelope-specific T-cell responses in patients with chronic hepatitis B	9
Burden, trends, and predictions of liver cancer in China, Japan, and South Korea: analysis based on the Global Burden of Disease Study 2021	9
Epidemiology and outcomes of primary sclerosing cholangitis: an Australian multicentre retrospective cohort study	9
Comments on: Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis	8
The clinical implications of pre-liver transplant diabetes on post-liver transplant outcomes in patients with NASH: analysis of the UNOS database	8
Lymphatic drainage dysfunction via narrowing of the lumen of cisterna chyli and thoracic duct after luminal dilation	8
Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated	8
Inflammation of the liver, HCC development and HCC establishment	8
Delicate and thin fibrous septa indicate a regression tendency in metabolic dysfunction-associated steatohepatitis patients with advanced fibrosis	8
Tertiary lymphoid structures as a potential prognostic biomarker for combined hepatocellular–cholangiocarcinoma	8
G-CSF treatment in decompensated liver disease: a double-edged sword?	8
Artificial intelligence in liver imaging: methods and applications	8
Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives	8
Incidence, risk factors, and outcomes of acute liver injury in hospitalized adults with acute kidney injury: a large multicenter study	8
MAFLD but not MASLD increases risk of all-cause mortality in regional Australia, with components of metabolic syndrome exacerbating factors: 20 year longitudinal, cohort study	8
Correction: Immunosuppression in adult liver transplant recipients: a 2024 update from the Italian Liver Transplant Working Group	8
MAFLD as part of systemic metabolic dysregulation	8
FXR overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in alcoholic liver disease	8
Acute-on-chronic liver failure in metabolic dysfunction-associated fatty liver disease patients: a disease multiplier	8
A preoperative scoring system to predict lymph node metastasis in intrahepatic cholangiocarcinoma	8
Chinese guidelines on the management of ascites in cirrhosis	8
Prognosis factors of predicting survival in spontaneously ruptured hepatocellular carcinoma	8
Alcohol-related hepatitis admissions decline in 2021 after a 2020 surge attributed to the COVID-19 pandemic	8
Treating extrahepatic portal-vein obstruction with cavernoma using radiological interventions: pushing the boundaries	8
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease	8
Systemic inflammatory response markers improve the discrimination for prognostic model in hepatocellular carcinoma	8
Integrating single-cell and bulk RNA sequencing reveals CK19 + cancer stem cells and their specific SPP1 + tumor-associated macrophage niche in HBV-related hepatocellular carcinoma	8
Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines	8
Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants	8
Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure	8
Asia–Pacific association for study of liver guidelines on management of ascites in liver disease	8
Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population	8
Correction to: The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study	8
Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV–DNA level < 2000 IU/mL	7
Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial	7
Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn’s disease but not Ulcerative Colitis: a prospective cohort study	7
First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients	7
Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice	7
Hepatitis B: “Treat all” or “Treat select”	7
Associations between intake of starchy and non-starchy vegetables and risk of hepatic steatosis and fibrosis	7
Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma	7
Targeting ferroptosis in hepatocellular carcinoma	7
Immune checkpoint inhibitors in chronic hepatitis B: therapy or high-risk factor for reactivation?	7
The contribution of genetics and epigenetics to MAFLD susceptibility	7
Clinic-radiomics model using liver magnetic resonance imaging helps predict chronicity of drug-induced liver injury	7
A prognostic model of acute-on-chronic liver failure based on sarcopenia	7
Non-invasive evaluation of NAFLD and the contribution of genes: an MRI-PDFF-based cross-sectional study	7
miR-488-5p mitigates hepatic stellate cell activation and hepatic fibrosis via suppressing TET3 expression	7
Primary prophylaxis of gastric variceal bleeding: the choices need to be tested!!	7
Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis	7
The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes	7
Cancer-associated fibroblasts in hepatocellular carcinoma: heterogeneity, mechanisms and therapeutic targets	7
Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma	7
Comparative accuracy of prognostic models for short-term mortality in acute-on-chronic liver failure patients: CAP-ACLF	7